GlaxoSmithKline has signed a license agreement with DSM Biologics and Crucell, allowing GSK to research a recombinant protein on the PER.C6 platform. Financial terms of the agreement were not disclosed.

"We are very pleased to enter into this collaboration with GSK," said Ronald Brus, Crucell's chief executive officer. "This agreement further underscores the potential of our PER.C6 production technology for generating recombinant proteins."

"The PER.C6 production technology continues to surpass our expectations as a robust manufacturing platform with its ever extending and global reach into the Research and Development departments of major healthcare players," Karen King, president of DSM Biologics, commented. "This agreement with GSK brings us closer to our mission of making the PER.C6 technology a gold standard for industry use."

News from our sister sites